The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
TNF/TNFR FAMILY MEMBERS IN COSTIMULATION OF T CELL RESPONSES
Watts, T. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115839 · Cited by 1,353
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889
Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Self-citationGhebeh, H., Mohammed, S., Al-Omair, A., Qattant, A., Lehe, C., Al-Qudaihi, G., Elkum, N., Alshabanah, M., Bin Amer, S., Tulbah, A., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612
Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0266-z · Cited by 473
Cutting Edge: 4-1BB Is a Bona Fide CD8 T Cell Survival Signal
Takahashi, C., Mittler, R. S., & Vella, A. T. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.9.5037 · Cited by 379
4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-1
Lee, H.-W., Park, S.-J., Choi, B. K., Kim, H. H., Nam, K.-O., & Kwon, B. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.4882 · Cited by 363
Fong, L., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 323
Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14184 · Cited by 259
Eradication of established tumors in mice by a combination antibody-based therapy
Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R. S., Gejyo, F., Okumura, K., Yagita, H., & Smyth, M. J. (2006) · Nature Medicine · doi:10.1038/nm1405 · Cited by 257
Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R., & Chen, L. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214184 · Cited by 222
Sznol, M., Hodi, F. S., Margolin, K., McDermott, D. F., Ernstoff, M. S., Kirkwood, J. M., Wojtaszek, C., Feltquate, D., & Logan, T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3007 · Cited by 204
Self-citationEnhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
Mangsbo, S. M., Sandin, L. C., Anger, K., Korman, A. J., Loskog, A., & Tötterman, T. H. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181c01fcb · Cited by 198
Li, B., VanRoey, M., Wang, C., Chen, T.-H. T., Korman, A., & Jooss, K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1825 · Cited by 191
Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease
Sun, Y., Chen, H. M., Subudhi, S. K., Chen, J., Koka, R., Chen, L., & Fu, Y.-X. (2002) · Nature Medicine · doi:10.1038/nm1202-796 · Cited by 181
Self-citationKocak, E., Lute, K., Chang, X., May, K. F., Exten, K. R., Zhang, H., Abdessalam, S. F., Lehman, A. M., Jarjoura, D., Zheng, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2128 · Cited by 177
Foell, J. L., Strahotin, S., O’Neil, S. P., McCausland, M. M., Suwyn, C. R., Haber, M., Chander, P. N., Bapat, A. S., Yan, X., Chiorazzi, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17662 · Cited by 176
Niu, L., Strahotin, S., Hewes, B., Zhang, B., Zhang, Y., Archer, D., Spencer, T., Dillehay, D., Kwon, B., Chen, L., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4194 · Cited by 171
Pilon‐Thomas, S., Mackay, A., Vohra, N. A., & Mulé, J. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904114 · Cited by 150
May, K. F., Chen, L., Zheng, P., & Liu, Y. (2002) · PubMed · Cited by 122
Dubrot, J., Milheiro, F., Alfaro, C., Palazón, A., Martínez‐Forero, I., Perez‐Gracia, J. L., Morales‐Kastresana, A., Romero-Trevejo, J. L., Ochoa, M. C., Hervás‐Stubbs, S., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0846-9 · Cited by 115
Self-citationIto, F., Li, Q., Shreiner, A. B., Okuyama, R., Jure‐Kunkel, M., Teitz‐Tennenbaum, S., & Chang, A. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0590 · Cited by 111
Wilcox, R. A., Tamada, K., Flies, D. B., Zhu, G., Chapoval, A. I., Blazar, B. R., Kast, W. M., & Chen, L. (2003) · Blood · doi:10.1182/blood-2003-06-2184 · Cited by 108
Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies
Melero, I., Murillo, O., Dubrot, J., Hervás‐Stubbs, S., & Perez‐Gracia, J. L. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.005 · Cited by 107
Self-citationCD137 Expression in Tumor Vessel Walls
Broll, K., Richter, G., Pauly, S., Hofstaedter, F., & Schwarz, H. (2001) · American Journal of Clinical Pathology · doi:10.1309/e343-kmyx-w3y2-10ky · Cited by 103
Sznol, M., Powderly, J. D., Smith, D. C., Brahmer, J. R., Drake, C. G., McDermott, D. F., Lawrence, D. P., Wolchok, J. D., Topalian, S. L., & Lowy, I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.2506 · Cited by 85
Self-citationCostimulation of human CD28– T cells by 4‐1BB ligand
Bukczynski, J., Wen, T., & Watts, T. H. (2003) · European Journal of Immunology · doi:10.1002/immu.200310020 · Cited by 72
Kwon, B., Kim, B.-S., Cho, H. R., Park, J.-E., & Kwon, B. S. (2003) · Experimental & Molecular Medicine · doi:10.1038/emm.2003.2 · Cited by 59
Zhang, B., Maris, C. H., Foell, J. L., Whitmire, J. K., Niu, L., Song, J., Kwon, B. S., Vella, A. T., Ahmed, R., Jacob, J., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32426 · Cited by 59
Kim, Y. H., Choi, B. K., Kim, K. H., Kang, S. W., & Kwon, B. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1365 · Cited by 59
In vivo depletion of DC impairs the anti‐tumor effect of agonistic anti‐CD137 mAb
Murillo, O., Dubrot, J., Palazón, A., Arina, A., Azpilikueta, A., Alfaro, C., Solano, S., Ochoa, M. C., Berasain, C., Gabari, I., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200838958 · Cited by 51
Self-citationNarazaki, H., Zhu, Y., Luo, L., Zhu, G., & Chen, L. (2010) · Blood · doi:10.1182/blood-2008-12-192591 · Cited by 50
Significance of B7-H1 Overexpression in Kidney Cancer
Thompson, R. H., & Kwon, E. D. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.038 · Cited by 45
Lin, G. H. Y., Liu, Y., Ambagala, T., Kwon, B. S., Ohashi, P. S., & Watts, T. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011003 · Cited by 44
Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination
Melero, I., Martínez‐Forero, I., Dubrot, J., Suárez, N., Palazón, A., & Chen, L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2931 · Cited by 26
Self-citationPerez‐Gracia, J. L., Berraondo, P., Martínez‐Forero, I., Alfaro, C., Suárez, N., Gúrpide, A., Sangro, B., Hervás‐Stubbs, S., Ochoa, C., Melero, J. A., et al. (2009) · Immunotherapy · doi:10.2217/imt.09.51 · Cited by 17
Self-citation
Cited by
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,184
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Metadata
- Authors
- Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y.-X., & Melero, I.
- Venue
- Seminars in Oncology
- Publisher
- Elsevier BV
- Published
- 2010-10
- Volume
- 37
- Issue
- 5
- Pages
- 508-516
- ISSN
- 0093-7754 (ISSN-L)
- OpenAlex
- W1992546156
- Cited by
- 276
- References
- 41
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.